• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco Releases 2024 Impact Report and Introduces New Framework

    6/26/25 1:00:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    GREENFIELD, Ind., June 26, 2025 /PRNewswire/ -- Today, Elanco Animal Health Incorporated (NYSE:ELAN) announced the release of its 2024 Impact Report, showcasing its efforts to enhance animal care, not just improving the lives of animals but also the people who care for them. Reflecting on its purpose and strategic alignment, the report introduces a new framework centered on four key communities of impact, celebrating Elanco's culture of 'Going Beyond' for animals, customers, society, and our people.

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    In launching a new approach to impact reporting, Elanco reaffirms its dedication to delivering lasting positive change. The report outlines eight core ambitions that shape Elanco's business and aim to generate a meaningful impact within the communities we serve worldwide.

    "Elanco is dedicated to delivering positive impact through the work we do every day, bringing innovative solutions to veterinarians, farmers, and pet owners," said Jeff Simmons, President & CEO of Elanco. "We're proud to announce a new framework that further embeds our purpose within our business operations, driving growth, accountability, and lasting positive change for society. We celebrate the progress made for these communities of impact and remain committed to advancing our objectives while delivering meaningful value to all our stakeholders."

    Key Highlights include:

    Go Beyond for Animals: Our strong portfolio, high-impact innovation, unique market approach, and dedication to making life better compels us to Go Beyond for Animals.

    • Brought key innovations to market, such as Zenrelia, Credelio Quattro, and Pradalex, driving $461 million in revenue in 2024, surpassing our innovation revenue contribution target of $420 million to $450 million.
    • Increased pet owner access to parasite protection: Ranked as #1 retail parasiticide dispensing in the U.S. while expanding global retail offerings with AdTab and the U.S. launch of Pet Protect, a new line of veterinary-formulated pet supplements under the Advantage family umbrella.
    • Donated more than $400,000 worth of products through partnerships to support animal health and wellbeing.
    • Served as an inaugural signatory to the U.S. Animal Research Openness Agreement (USARO), reinforcing Elanco's commitment to transparency in the use of animals in research.

    Go Beyond for Customers: Our promise to advocate, earn trust, and solve big challenges to create value inspires us to Go Beyond for Customers.

    • Launched Bovaer®, a first-of-its-kind methane-reducing feed ingredient for lactating dairy cattle.
    • Advanced livestock sustainability with FDA approval of three combination clearances for Experior use with MGA® in finishing heifers.
    • Enrolled 11% of the U.S. dairy herd into Elanco's UpLook database, a digital insights engine that helps farmers measure and track sustainability goals; allowing U.S. dairy farmers to earn around $10 million in net returns from monetizing carbon credit reductions using Rumensin.
    • Committed $310,000 in scholarships to support the advanced education of students entering the field of veterinary science and animal health.

    Go Beyond for Society: Our commitment to improving the health of people through animals, delivering reliable products, and safeguarding the food system drives us to Go Beyond for Society.

    • Educated nearly 150 global producers via the Elanco Food Safety Programme to tackle Salmonella outbreaks in poultry.
    • Dedicated over 730 volunteer hours in food pantries, collaborating with meal-packing organizations to pack over 115,000 meals in 2024.
    • Recovered over $7 million worth of counterfeit products and removed over 700,000 suspect online product advertisements since 2021.
    • Engaged in strategic partnership with Medgene to leverage innovative vaccine technology, including the commercialization of a Highly Pathogenic Avian Influenza (HPAI) vaccine for dairy cattle, once approved.

    Go Beyond for Our People: Our unique purpose-driven culture encourages ownership, growth, and wellbeing, motivating us to Go Beyond for Our People.

    • Achieved a 71% Employee Engagement Score as of Q1 2025, noting a 4% increase from the same period a year ago.
    • Recorded more than 26,000 volunteer hours in 2024, contributing $870,000 in estimated value of volunteerism across 1,100 global organizations.
    • Introduced a global machine safety campaign for personal health, safety, and environment (HSE), resulting in a 37% decrease in Days Away, Restricted, or Transferred (DART).
    • Successfully improved energy efficiency at the Kiel facility with an innovative HVAC system, achieving 100% renewable green electricity and 100% neutral natural gas, compensated by certification.

    Elanco invites all stakeholders to explore the full 2024 Impact Report and looks forward to further advancing our purpose of Making Life Better for animals, customers, society, and our people in everything we do.

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

    Investor Contact: Tiffany Kanaga (765) 740-0314 or [email protected] 

    Media Contact: Colleen Parr Dekker (317) 989-7011 or [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-releases-2024-impact-report-and-introduces-new-framework-302492454.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    1/5/2024$13.00 → $20.00Hold → Buy
    Stifel
    12/19/2023$17.00Buy
    Jefferies
    12/15/2023$16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs

    The European Commission's Approval of Zenrelia reinforces safety and efficacy and further expands opportunities to treat itchy dogs around the worldLaunch to begin immediately with product in market before the end of Q3 2025GREENFIELD, Ind., July 24, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) announced today that Zenrelia™ (ilunocitinib) has received approval by the European Commission. This approval by the EU reinforces Zenrelia's status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia's approval represents a signific

    7/24/25 5:42:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    SEC Form 144 filed by Elanco Animal Health Incorporated

    144 - Elanco Animal Health Inc (0001739104) (Subject)

    8/11/25 3:58:15 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Elanco Animal Health Incorporated

    10-Q - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 9:05:13 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    8/7/25 6:27:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Elanco Animal Health from Market Perform to Outperform and set a new price target of $18.00

    7/17/25 7:51:30 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by William Blair

    William Blair upgraded Elanco Animal Health from Mkt Perform to Outperform

    6/26/25 7:49:03 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Elanco Animal Health with a new price target

    UBS initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $18.00

    12/9/24 7:40:18 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:55:46 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/12/25 5:54:06 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    7/29/25 4:24:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports First Quarter 2025 Results

    Accelerating Debt Paydown in 2025 First Quarter 2025 Financial Results:Revenue of $1,193 million, a decline of 1% year-over-year; 4% organic constant currency growthReported Net Income of $67 million, Adjusted Net Income of $184 millionAdjusted EBITDA of $276 million, or 23.1% of RevenueReported EPS of $0.13, Adjusted EPS of $0.37Net leverage ratio of 4.4x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,510 to $4,580 million, with $65 to $70 million increase since February driven by foreign exchange tailwind; continue to expect accelerating organic constant currency revenue growth to mid-single digitsRaising 2025 innovation revenue target to $660 to $740 millionReported

    5/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

    GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

    5/28/25 7:25:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Strengthens Board of Directors with Addition of Stacey Ma

    Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen

    11/12/24 8:33:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care